Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Testando a adição de uma droga anticancerígena, Selinexor, ao tratamento quimioterápico usual (Temozolomida) para tumores cerebrais que retornaram após tratamento anterior

6 de novembro de 2026 atualizado por: National Cancer Institute (NCI)

Um estudo de fase 1/2 de selinexor e temozolomida em glioblastoma recorrente

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozolomide) in treating patients with glioblastoma that has come back (recurrent). Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Giving selinexor in combination with usual chemotherapy (temozolomide) may shrink or stabilize the tumor better than the usual chemotherapy with temozolomide alone in patients with recurrent glioblastoma.

Visão geral do estudo

Descrição detalhada

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as determined by dose-limiting toxicities (DLTs) and the total toxicity profile. (Phase I) II. To evaluate the efficacy of sequentially administering temozolomide and selinexor in recurrent glioblastoma as determined by progression-free survival (PFS). (Phase II)

SECONDARY OBJECTIVES:

I. To evaluate overall response rate as determined by Response Assessment in Neuro-Oncology (RANO) response criteria.

II. To evaluate the efficacy of sequentially administering temozolomide and selinexor in recurrent glioblastoma as determined by 6-month PFS (6mPFS) and overall survival (OS).

III. To validate signatures of vulnerability to predict response to selinexor through ribonucleic acid (RNA) sequencing for 6 top-scoring gene pairs, whole exome sequencing, P53, EGFR, and Mcl-1.

OUTLINE: This is a phase I, dose-escalation study of selinexor in combination with fixed dose temozolomide followed by a phase II study that compares selinexor temozolomide combination therapy vs. temozolomide monotherapy. Patients are randomized to 1 of 2 groups for the phase II part of this trial.

GROUP I (Phase II): Patients receive temozolomide orally (PO) once daily (QD) on days 1-5 of each cycle and placebo PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

GROUP II (Phase I and II): Patients receive temozolomide PO QD on days 1-5 of each cycle and selinexor PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Phase I completed as of April 2024)

Patients undergo magnetic resonance imaging (MRI) throughout the study and blood sample collection while on study.

After completion of study treatment, patients are followed up every 2 months up to 2 years.

Tipo de estudo

Intervencional

Inscrição (Estimado)

97

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85054
        • Recrutamento
        • Mayo Clinic Hospital in Arizona
        • Contato:
        • Investigador principal:
          • Alyx B. Porter Umphrey
    • California
      • Duarte, California, Estados Unidos, 91010
        • Recrutamento
        • City of Hope Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Jana L. Portnow
      • Irvine, California, Estados Unidos, 92612
        • Recrutamento
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Contato:
          • Site Public Contact
          • Número de telefone: 877-827-8839
          • E-mail: ucstudy@uci.edu
        • Investigador principal:
          • Frances E. Chow
      • La Jolla, California, Estados Unidos, 92093
        • Recrutamento
        • UC San Diego Moores Cancer Center
        • Contato:
        • Investigador principal:
          • David E. Piccioni
      • Los Angeles, California, Estados Unidos, 90033
        • Recrutamento
        • USC / Norris Comprehensive Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 323-865-0451
        • Investigador principal:
          • Jacob S. Thomas
      • Los Angeles, California, Estados Unidos, 90020
        • Recrutamento
        • Keck Medicine of USC Koreatown
        • Contato:
          • Site Public Contact
          • Número de telefone: 213-388-0908
        • Investigador principal:
          • Jacob S. Thomas
      • Los Angeles, California, Estados Unidos, 90033
        • Recrutamento
        • Los Angeles General Medical Center
        • Investigador principal:
          • Jacob S. Thomas
        • Contato:
      • Orange, California, Estados Unidos, 92868
        • Recrutamento
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 877-827-8839
          • E-mail: ucstudy@uci.edu
        • Investigador principal:
          • Frances E. Chow
      • Sacramento, California, Estados Unidos, 95817
        • Recrutamento
        • University of California Davis Comprehensive Cancer Center
        • Investigador principal:
          • Orwa Aboud
        • Contato:
          • Site Public Contact
          • Número de telefone: 916-734-3089
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Recrutamento
        • UCHealth University of Colorado Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 720-848-0650
        • Investigador principal:
          • Denise M. Damek
    • Florida
      • Coral Gables, Florida, Estados Unidos, 33146
        • Recrutamento
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
        • Contato:
          • Site Public Contact
          • Número de telefone: 305-243-2647
        • Investigador principal:
          • Macarena I. De La Fuente
      • Deerfield Beach, Florida, Estados Unidos, 33442
        • Recrutamento
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
        • Contato:
          • Site Public Contact
          • Número de telefone: 305-243-2647
        • Investigador principal:
          • Macarena I. De La Fuente
      • Jacksonville, Florida, Estados Unidos, 32224-9980
        • Recrutamento
        • Mayo Clinic in Florida
        • Contato:
          • Site Public Contact
          • Número de telefone: 855-776-0015
        • Investigador principal:
          • Sani H. Kizilbash
      • Miami, Florida, Estados Unidos, 33136
        • Recrutamento
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 305-243-2647
        • Investigador principal:
          • Macarena I. De La Fuente
      • Tampa, Florida, Estados Unidos, 33612
        • Recrutamento
        • Moffitt Cancer Center
        • Contato:
        • Investigador principal:
          • Patrick T. Grogan
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Recrutamento
        • Emory University Hospital/Winship Cancer Institute
        • Investigador principal:
          • Kimberly Hoang
        • Contato:
          • Site Public Contact
          • Número de telefone: 404-778-1868
      • Atlanta, Georgia, Estados Unidos, 30308
        • Recrutamento
        • Emory University Hospital Midtown
        • Investigador principal:
          • Kimberly Hoang
        • Contato:
          • Site Public Contact
          • Número de telefone: 888-946-7447
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • University of Chicago Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Lauren Singer
      • Orland Park, Illinois, Estados Unidos, 60462
        • Recrutamento
        • University of Chicago Medicine-Orland Park
        • Contato:
        • Investigador principal:
          • Lauren Singer
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • Recrutamento
        • University of Kentucky/Markey Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 859-257-3379
        • Investigador principal:
          • John L. Villano
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Recrutamento
        • Mayo Clinic in Rochester
        • Contato:
          • Site Public Contact
          • Número de telefone: 855-776-0015
        • Investigador principal:
          • Sani H. Kizilbash
    • New Jersey
      • Livingston, New Jersey, Estados Unidos, 07039
        • Recrutamento
        • Cooperman Barnabas Medical Center
        • Investigador principal:
          • Andrew B. Brown
        • Contato:
          • Site Public Contact
          • Número de telefone: 973-322-5200
      • New Brunswick, New Jersey, Estados Unidos, 08903
        • Recrutamento
        • Rutgers Cancer Institute of New Jersey
        • Contato:
          • Site Public Contact
          • Número de telefone: 732-235-7356
        • Investigador principal:
          • Andrew B. Brown
      • Newark, New Jersey, Estados Unidos, 07101
        • Recrutamento
        • Rutgers New Jersey Medical School
        • Contato:
          • Site Public Contact
          • Número de telefone: 732-235-7356
        • Investigador principal:
          • Andrew B. Brown
    • New York
      • Buffalo, New York, Estados Unidos, 14263
        • Ativo, não recrutando
        • Roswell Park Cancer Institute
      • New York, New York, Estados Unidos, 10032
        • Recrutamento
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Peter C. Pan
      • New York, New York, Estados Unidos, 10016
        • Recrutamento
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
        • Contato:
        • Investigador principal:
          • Jose R. McFaline Figueroa
    • North Carolina
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Recrutamento
        • Wake Forest University Health Sciences
        • Contato:
          • Site Public Contact
          • Número de telefone: 336-713-6771
        • Investigador principal:
          • Roy E. Strowd
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • Recrutamento
        • University of Cincinnati Cancer Center-UC Medical Center
        • Contato:
        • Investigador principal:
          • Lalanthica V. Yogendran
      • Cleveland, Ohio, Estados Unidos, 44195
        • Recrutamento
        • Cleveland Clinic Foundation
        • Investigador principal:
          • David M. Peereboom
        • Contato:
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • Ohio State University Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Pierre Giglio
      • West Chester, Ohio, Estados Unidos, 45069
        • Recrutamento
        • University of Cincinnati Cancer Center-West Chester
        • Contato:
        • Investigador principal:
          • Lalanthica V. Yogendran
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Recrutamento
        • University of Oklahoma Health Sciences Center
        • Contato:
        • Investigador principal:
          • James D. Battiste
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • Recrutamento
        • UPMC Hillman Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 412-647-8073
        • Investigador principal:
          • Megan Mantica
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Suspenso
        • Huntsman Cancer Institute/University of Utah
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • Ativo, não recrutando
        • University of Virginia Cancer Center
      • Richmond, Virginia, Estados Unidos, 23298
        • Ativo, não recrutando
        • VCU Massey Comprehensive Cancer Center
    • Wisconsin
      • Madison, Wisconsin, Estados Unidos, 53792
        • Recrutamento
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • Investigador principal:
          • Ankush Bhatia
        • Contato:
      • Madison, Wisconsin, Estados Unidos, 53718
        • Recrutamento
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
        • Investigador principal:
          • Ankush Bhatia
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Patients must have histologically confirmed glioblastoma (IDH wild-type, MGMT promoter methylated) that has undergone resection or biopsy upon first recurrence. Recurrence at site of prior involvement is defined by histopathological evidence of viable neoplastic cells associated with any of the following: mitotic activity, increased proliferation rate, micro-endothelial proliferation, or pseudo-palisading necrosis
  • Prior to resection or biopsy, patients must have measurable disease, defined as at least one bi-dimensional contrast-enhancing lesion with clearly defined margins, with 2 perpendicular diameters of at least 10 mm, visible on >= 2 axial slices
  • Patients must have received first-line treatment of temozolomide plus radiotherapy
  • Patients must not have received any prior therapy aside from resection or biopsy for their recurrent disease
  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of selinexor (KPT-330) in combination with temozolomide in patients < 18 years of age, children are excluded from this study
  • Karnofsky performance status >= 60% (Eastern Cooperative Oncology Group [ECOG] =< 2)
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Hemoglobin >= 10 g/dL
  • Total bilirubin =< 2 x institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine transaminase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) =< 3 x institutional ULN
  • Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
  • The effects of selinexor (KPT-330) and temozolomide on the developing human fetus are unknown. For this reason and because selective nuclear export inhibitors as well as deoxyribonucleic acid (DNA) alkylating agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and for 180 days after the last dose of temozolomide. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 90 days after completion of study treatment administration
  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity who have a legally-authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

  • Patients who have had chemotherapy must have full recovery of organ and marrow function following the nadir of the last chemotherapy cycle
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
  • Patients who are receiving any other investigational agents
  • Patients who have previously received bevacizumab
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor (KPT-330) or temozolomide
  • History of hypersensitivity to dacarbazine (DTIC), since both dacarbazine and temozolomide are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC)
  • Patients with uncontrolled intercurrent illness
  • Pregnant women are excluded from this study because selinexor (KPT-330) is a selective inhibitor of nuclear export with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with selinexor (KPT-330), breastfeeding is not allowed for mothers during treatment with selinexor (KPT-330) and for 7 days after the last dose. These potential risks may also apply to other agents used in this study
  • Hospitalized patients with severe coronavirus disease of 2019 (COVID-19) who are >= 75 years old, or with a high-risk COVID-GRAM score, or with lactate dehydrogenase (LDH) > 370 (U/L) AND D-Dimer > 600 mcg/L FEU should not receive low-dose selinexor (KPT-330) pending additional results

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Group I (temozolomide)

Patients receive temozolomide PO QD on days 1-5 of each cycle and placebo PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Undergo blood sample collection

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância Magnética (MRI)
  • ressonância magnética
  • Ressonância magnética (procedimento)
  • Ressonâncias magnéticas
  • RM estrutural

Given PO

Outros nomes:
  • Temodar
  • SCH 52365
  • Temodal
  • Temcad
  • Metazolastona
  • RP-46161
  • Temomedac
  • TMZ
  • CCRG-81045
  • Imidazo[5,1-d]-1,2,3,5-tetrazina-8-carboxamida, 3,4-dihidro-3-metil-4-oxo-
  • M&B 39831
  • M e B 39831
  • Gliotem
  • Temizol

Given PO

Experimental: Group II (temozolomide, selinexor)

Patients receive temozolomide PO QD on days 1-5 of each cycle and selinexor PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the study and blood sample collection while on study.

Undergo blood sample collection

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância Magnética (MRI)
  • ressonância magnética
  • Ressonância magnética (procedimento)
  • Ressonâncias magnéticas
  • RM estrutural

Given PO

Outros nomes:
  • Temodar
  • SCH 52365
  • Temodal
  • Temcad
  • Metazolastona
  • RP-46161
  • Temomedac
  • TMZ
  • CCRG-81045
  • Imidazo[5,1-d]-1,2,3,5-tetrazina-8-carboxamida, 3,4-dihidro-3-metil-4-oxo-
  • M&B 39831
  • M e B 39831
  • Gliotem
  • Temizol

Given PO

Outros nomes:
  • ATG-010
  • Inibidor de Exportação Nuclear CRM1 KPT-330
  • KPT-330
  • Inibidor Seletivo de Exportação Nuclear KPT-330
  • SINE KPT-330
  • Xpovio
  • Nexovio
  • KPT 330
  • KPT330

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Recommended phase 2 dose (RP2D) (Phase I)
Prazo: Up to 28 days

Any eligible patient who receives at least one dose of protocol-defined therapy will be considered evaluable for dose-limiting toxicity (DLT) if either of the following occurs: (1) the patient experiences a DLT during cycle 1 of therapy; or (2) the patient receives at least 4 doses of temozolomide and 1 dose of selinexor. All other patients enrolled during the phase 1 portion of the study will be considered inevaluable for DLT and may be replaced for the purposes of establishing the RP2D.

Up to 28 days
Progression-free survival (PFS) (Phase II)
Prazo: From randomization to date of disease progression (either progression of existing lesions or appearance of new lesions), death, or date of last contact, whichever occurs first, assessed up to 3 years

Patients who experience disease progression or death will be considered to have experienced a PFS-event; otherwise the patient is considered censored at last contact.

From randomization to date of disease progression (either progression of existing lesions or appearance of new lesions), death, or date of last contact, whichever occurs first, assessed up to 3 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Response according to response assessment in neuro-oncology criteria (RANO) criteria
Prazo: Up to 3 years

A patient who is evaluated as complete response, partial response, or stable disease will be considered a RANO-responder. All other patients will be considered RANO-non-responders. Response rate will be calculated and comparisons made using categorical data methods.

Up to 3 years
Six-month progression-free survival (PFS-6)
Prazo: At 6 months

Any patient considered evaluable for RANO response will be considered evaluable for PFS-6. Any evaluable patient who is considered progression free for the primary analysis will be considered a PFS-6 responder. All other evaluable patients will be considered PFS-6 non-responders.

At 6 months
Median overall survival
Prazo: Time between the date of randomization and the date of death or date of last contact, whichever occurs first, assessed up to 3 years

Will be calculated from the Kaplan-Meier estimate of the probability of death as a function of time since enrollment. Ninety-five percent (95%) confidence intervals will be calculated as well.

Time between the date of randomization and the date of death or date of last contact, whichever occurs first, assessed up to 3 years
Molecular signatures of vulnerability
Prazo: Up to 3 years

Will be assessed using logistic regression for the outcome measure (RANO response) and using proportional hazard regression with the biological characteristic of interest as the predictor variable for risk for PFS event. Patients considered evaluable for RANO response and PFS, respectively, will contribute to the analyses for these exploratory outcomes. Two-sided statistical testing will be employed, and a p-value of 0.05 or less will be considered as indicating significant evidence of association between the particular signature and the outcome of interest.

Up to 3 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Jana L Portnow, City of Hope Comprehensive Cancer Center LAO

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de março de 2023

Conclusão Primária (Estimado)

30 de junho de 2027

Conclusão do estudo (Estimado)

30 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

22 de junho de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de junho de 2022

Primeira postagem (Real)

27 de junho de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever